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Aspirin Use and AgingMacula Disorder
For nearly half a century, associations between aspi-
rin use and aging macula disorder (also termed age-
related macular degeneration [both AMD]) have been
described, predominantly from case reports and small
clinical studies. In the last year, the publication ofmore
robust evidence from 3 population-based studies has
reawakened interest in this question.1-3
One cross-sectional1 and 2 prospective2,3 studies
foundan increased riskofAMDwith regular aspirin use.
In the cross-sectional European Eye Study, the odds ra-
tio for neovascular AMD (nAMD) rose with more fre-
quent aspirin use, and for daily aspirin use, the odds ra-
tiowas2.22(95%CI, 1.61-3.05).1 In the20-year follow-up
of theBeaverDamEyeStudy, the risk for incidentnAMD
with regular use of aspirin, as reported 10 years previ-
ously, was 2.20 (95% CI, 1.20-4.15).2 In the 15-year fol-
low-up of the Blue Mountains Eye Study, the cumula-
tive risk of regular use of aspirin for incident nAMDwas
2.46 (95%CI, 1.25-4.83).3Noneof the studies foundan
associationwithgeographicatrophy, thedry formof late
AMD. The European Eye Study also found an associa-
tion with early AMD.1
Giventheestimated 19%of theUSpopulationusing
aspirin regularly,2 these results warrant closer scrutiny.
The 3 studies1-3 were observational studies and limita-
tions in studydesignneed tobe considered. Confound-
ing by indication or “indication bias,” a major concern
when assessing drug-related risks in nonrandomized
studies, was examined in all 3 studies. The associations
of aspirin with AMD were not explained by cardiovas-
cular disease (CVD)history,1-3 themain reason for regu-
lar aspirin use. Nor was there any evidence that the ef-
fects of aspirin differed in thosewithCVD.1-3 In theBlue
MountainsEyeStudy, theoddsratios foraspirinusewere
higher in thosewith a history of CVDbut the number of
cases was small and the P value for effect modification
testing was .30. In the other studies, there was no sig-
nificanteffectmodificationandnodifference in theodds
ratios when stratified by CVD history.1,2
There was no association with other types of pain-
relievingmedicationsandAMD.3Althoughtherewas lim-
ited information on other conditions for which aspirin
mightbetaken,noassociationoreffectmodificationwas
found with a history of arthritis in the study that inves-
tigated this.2 Aspirin usewas self-reported in all studies
and in 2 studies2,3 corroborated with information from
prescriptionsoractualmedicationstheparticipantswere
using. Therewere no dosage data of aspirin, although 1
studyestimatedadaily dose inmilligramsand foundno
significant relationship between dose and early or late
AMD.2 Respondent errors in reporting aspirin use dose
and frequency are expected, especially over a long-
term follow-up period. These errors are likely to dilute
the observed associations. The number of nAMD cases
was low: of 10 212 participants in the 3 studies,1-3 208
(2%) were nAMD cases, 108 prevalent and 100 inci-
dent, leading to low power in subgroup analyses.
How do these results fit with other studies? Older
publications (reviewed in the European Eye Study
article1) oftenmixed anticoagulant and antiplatelet ag-
gregation drugs, were not prospective, andmostly had
no controls. Two randomized clinical trials, the Physi-
cians’ Health Study I4 and the Women’s Health Study,5
foundno effect of aspirin onAMDover the durations of
5 and 10 years. Age-related macular degeneration was
self-reported and confirmed by medical records. De-
spite the large sample sizes of the 2 trials (21 000 and
40 000, respectively), therewere very fewcases of vi-
sually impairing late AMD (12 nAMD and 4 geographic
atrophy)4 and 55 cases of combined nAMD and geo-
graphic atrophy,5 and AMD incidence was at least 10
times lower than in largepopulation-based studies.2,3,6
In theWomen’sHealthStudy, thehazard ratio for all late
AMD was 0.90 (95% CI, 0.53-1.52)5; no equivalent es-
timatewasprovided for thePhysicians’Health Study I.4
Neither trial presented the results by subtype of late
AMD. Low power and lack of results on nAMD make it
difficult toassess thecontributionof these2 trials to the
questionofwhether regularaspirinuse increases therisk
of nAMD.
The recent 3 studies1-3with validatedAMDdiagno-
sis based on fundus image grading showed similar as-
sociations, pointing to some consistency and specific-
ity of the association of regular aspirin use with nAMD
butnotwithgeographic atrophy. Theprospective stud-
ies imply that exposure to aspirin preceded the occur-
renceofAMD(temporality); the longer thefollow-up, the
stronger the association magnitude was in the Blue
MountainsEyeStudy;while in theBeaverDamEyeStudy,
use of aspirin, reported 10 years earlier but not 5 years
earlier, increased the riskof nAMD.Therewas someevi-
dence suggesting a dose-response pattern in the asso-
ciation, with increasing odds ratios for increasing fre-
quencyofaspirinuse inthe2studies1,3 thatassessedthis.
Thereare indications forbiologicalplausibility suchas in-
hibiting prostaglandin-endoperoxide synthetase 1 and
2by aspirin, inhibition of transporting protons, and for-
mation of nitric oxygen radicals.1 We therefore con-
clude that the evidence is sufficient to justify caution
about this potential long-term risk of nAMD associated
with regular use of aspirin.
The benefit of aspirin for secondary prevention of
CVD iswell established.Ameta-analysis of low-doseas-
pirin trials founda reduction in theannual recurrenceof
seriousvascularevents (6.7%in those randomizedtoas-
pirin compared with 8.2% in controls).7 For those with
nohistoryofCVD(primaryprevention), thebenefitwas
substantially less (0.51% annual incidence with aspirin
compared with 0.57% in controls), reflecting a much
lower absolute risk reduction in thosewithnohistoryof
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CVD. Conversely, in the primary prevention group, aspirin was as-
sociated with an increase in adverse events. There was no benefit
in ischemic stroke, an increase in hemorrhagic stroke, and an in-
crease in gastrointestinal and extracranial bleeding.
What should ophthalmologists advise their patients in light of
these findings? The small risk of regular aspirin use in nAMD, a se-
rious but uncommon condition, needs to be balanced against the
benefit of aspirin togetherwithother varying risks, according to the
individual patient's conditions and CVD risk factors, including age.
It would seem prudent that ophthalmologists advise patients with
known AMD in at least 1 eye and no history of CVD to consult their
family physicians or cardiologists as to whether regular aspirin use
as primary CVD prevention is warranted. Recommendations for
aspirin use might be better individually tailored in the future, with
improvedpredictionmodels forAMD,basedonenvironmental and
genetic profiles.
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